Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00396110

Enrollment

3889

Registered

2006-11-06

Start date

2003-02-28

Completion date

Unknown

Last updated

2006-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease, Hypercholesterolemia

Keywords

cholesterol, coronary heart disease, rosuvastatin, LDL-C goal, hypercholesterolemia

Brief summary

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C \< 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* High-risk patients with and without evident CHD who had LDL-C \> 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin. * Patients were aged \>18 years and \<70 years (men) and \< 75 years (women).

Exclusion criteria

* Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg * Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin

Outcome results